-transparent.png){kind=logo}
The effect of human recombinant interleukin-1 beta (hrIL-1 beta) on tumor growth was studied in eight glioma cell lines. hrIL-1 beta inhibited growth in all cell lines, but to varying extents. Two cell lines were suppressed by 0.5 ng/ml hrIL-1 beta, and three cell lines required 20 ng/ml. hrIL-1 beta also induced morphological changes and increased F-actin contents. hrIL-1 beta-treated cells demonstrated multipolar shapes and numerous processes with a greater number of cell-cell contacts 24 hours after treatment. Fluorescence microscopy revealed that these processes contained a large amount of polymerized F-actin. These results suggest that hrIL-1 beta-mediated growth inhibition may be related to the differentiation of glioma cells.
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
March 1996,
Neurologia medico-chirurgica,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
August 1999,
International journal of cancer,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
May 1992,
Journal of neuro-oncology,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
October 1995,
Neurologia medico-chirurgica,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
February 1989,
Experientia,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
October 1983,
Gan,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
October 1992,
Immunology,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
December 1995,
Cancer research,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
September 1990,
Journal of cellular physiology,
H Koga, and
J Mukawa, and
K Miyagi, and
Y Higa, and
S Nakasone, and
S Mekaru, and
M Ingram
July 1995,
Neurologia medico-chirurgica,
